StoxGlenmark Pharmaceuticals vs Biocon: share price & financials comparison
NSE: GLENMARK vs BIOCON · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Glenmark Pharmaceuticals vs Biocon at a glance
Glenmark Pharmaceuticals (GLENMARK) has a market capitalisation of ₹73,095 Cr, against ₹59,497 Cr for Biocon (BIOCON). Over the past year Glenmark Pharmaceuticals has returned +40.5%, compared with -2.3% for Biocon. On valuation, Glenmark Pharmaceuticals trades at a lower P/E of 82.5 versus 131.6. Glenmark Pharmaceuticals earns a higher return on equity (7.9% vs 1.3%). Glenmark Pharmaceuticals comes out ahead on valuation, profitability, financial health, momentum and technicals. Biocon comes out ahead on size and growth. Across the scored metrics below, Glenmark Pharmaceuticals leads on 12 and Biocon on 6. On StoxGud's 10-point checklist, Glenmark Pharmaceuticals scores 5/10 and Biocon scores 3/10.
| Metric | Glenmark Pharmaceuticals | Biocon |
|---|---|---|
| Size | ||
| Market cap | ₹73,095 Cr | ₹59,497 Cr |
| Revenue (latest FY) | ₹16,983 Cr | ₹16,927 Cr |
| Net profit (latest FY) | ₹0 Cr | ₹386 Cr |
| Valuation | ||
| P/E | 82.5 | 131.6 |
| P/B | 6.52 | 1.71 |
| Dividend yield | 0.19% | 0.15% |
| Profitability | ||
| Return on equity | 7.9% | 1.3% |
| Net profit margin | 5.6% | 2.6% |
| Operating margin | 20.3% | 20.3% |
| Growth | ||
| Revenue growth (YoY) | -31.3% | +2.2% |
| Net profit growth (YoY) | -100.0% | -51.1% |
| Revenue CAGR (multi-year) | +9.2% | +19.0% |
| Financial health | ||
| Debt to equity | 0.08 | 0.43 |
| Momentum | ||
| 1-month return | +13.5% | +1.4% |
| 1-year return | +40.5% | -2.3% |
| 3-year CAGR | +50.8% | +17.5% |
| 5-year CAGR | +37.6% | +0.9% |
| 10-year CAGR | +11.2% | +9.3% |
| Distance from 52W high | +0.0% | -17.2% |
| Technicals | ||
| RSI (14) | 79 | 59 |
| Price vs 200-day avg | +15.9% | -6.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Glenmark Pharmaceuticals | Biocon |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 5/10 | 3/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Glenmark Pharmaceuticals or Biocon?
Glenmark Pharmaceuticals has a market cap of ₹73,095 Cr and Biocon has a market cap of ₹59,497 Cr as of 06 Nov 2026.
Which has a lower P/E, Glenmark Pharmaceuticals or Biocon?
Glenmark Pharmaceuticals has the lower P/E: Glenmark Pharmaceuticals trades at 82.5 and Biocon at 131.6.
Which gave better returns in the last year, Glenmark Pharmaceuticals or Biocon?
Glenmark Pharmaceuticals did better: Glenmark Pharmaceuticals returned +40.5% and Biocon returned -2.3% over one year.
Is Glenmark Pharmaceuticals or Biocon a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Glenmark Pharmaceuticals scores 5/10 and Biocon scores 3/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.